Breaking News Instant updates and real-time market news.

CDLX

Cardlytics

$39.85

0.17 (0.43%)

, TWOU

2U

$22.58

0.77 (3.53%)

18:44
11/12/19
11/12
18:44
11/12/19
18:44

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Cardlytics (CDLX) up 24.2%... 2U (TWOU) up 14.5%... Opiant Pharma (OPNT) up 13.7%... DataDog (DDOG) up 13.3%... Polarity (PTE) up 8.3%... Adaptive Biotech (ADPT) up 5.8%... ADT Inc (ADT) up 5.8%... BioDelivery Sciences (BDSI) up 5.0%... Aqua Metals (AQMS) up 4.8%... YY (YY) up 4.0%... Huya (HUYA) up 3.9%... SunRun (RUN) up 2.9%... ViewRay (VRAY) up 2.8%... DASAN Zhone Solutions (DZSI) up 2.4%... Health Insurance Innovations (HIIQ) up 2.1%... Continental Building (CBPX) up 1.5%. ALSO HIGHER: Kinsale Capital (KNSL) up 8.2% after entering S&P SmallCap 600 index. DOWN AFTER EARNINGS: Boxlight (BOXL) down 15.3%... ShotSpotter (SSTI) down 12.1%... Tivity Health (TVTY) down 11.9%... Gevo (GEVO) down 9.8%... Canadian Solar (CSIQ) down 9.5%... SmileDirectClub (SDC) down 7.3%... Skyworks (SWKS) down 5.2%... Varex Imaging (VREX) down 3.6%... Tilray (TLRY) down 2.2%. ALSO LOWER: NextCure (NXTC) down 8.9% after equity offering... Halozyme (HALO) down 4.9% after convertible debt offering... CyberArk Software (CYBR) down 3.0% after convertible debt offering... Intelsat (I) down 2.9% after being downgraded to Neutral at JPMorgan. Movers as of 18:15ET.

CDLX

Cardlytics

$39.85

0.17 (0.43%)

TWOU

2U

$22.58

0.77 (3.53%)

OPNT

Opiant Pharmaceuticals

$15.95

0.18 (1.14%)

DDOG

Datadog

$34.40

0.89 (2.66%)

PTE

PolarityTE

$2.89

-0.41 (-12.42%)

ADPT

Adaptive Biotechnologies

$28.35

0.01 (0.04%)

ADT

ADT Inc.

$7.70

-0.02 (-0.26%)

BDSI

BioDelivery Sciences

$5.86

0.02 (0.34%)

AQMS

Aqua Metals

$1.45

-0.065 (-4.29%)

YY

YY

$65.12

-0.28 (-0.43%)

HUYA

Huya

$24.28

-1.05 (-4.15%)

RUN

Sunrun

$14.49

0.08 (0.56%)

VRAY

ViewRay

$2.48

-0.145 (-5.53%)

DZSI

Dasan Zhone

$8.34

0.5 (6.38%)

HIIQ

Health Insurance Innovations

$23.27

-1.71 (-6.85%)

CBPX

Continental Building

$35.76

3.73 (11.65%)

KNSL

Kinsale Capital Group

$88.98

1.78 (2.04%)

BOXL

Boxlight

$1.94

0.19 (10.86%)

SSTI

ShotSpotter

$20.36

(0.00%)

TVTY

Tivity Health

$18.56

0.145 (0.79%)

GEVO

Gevo

$2.57

0.065 (2.59%)

CSIQ

Canadian Solar

$17.51

0.65 (3.86%)

SDC

SmileDirectClub

$11.02

-0.83 (-7.00%)

SWKS

Skyworks

$101.59

1.22 (1.22%)

VREX

Varex Imaging

$32.68

0.1 (0.31%)

TLRY

Tilray

$21.57

-0.4 (-1.82%)

NXTC

NextCure

$37.41

-1.45 (-3.73%)

HALO

Halozyme

$16.77

0.18 (1.09%)

CYBR

CyberArk

$115.30

1.45 (1.27%)

I

Intelsat

$20.39

-2.845 (-12.24%)

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 03

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 17

    Dec

  • 15

    Nov

CDLX Cardlytics
$39.85

0.17 (0.43%)

08/08/19
KEYB
08/08/19
DOWNGRADE
KEYB
Sector Weight
Cardlytics downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Andy Hargreaves downgraded Cardlytics to Sector Weight.
08/09/19
08/09/19
DOWNGRADE

Sector Weight
Cardlytics downgraded to Sector Weight from Overweight at KeyBanc
As previously reported, KeyBanc analyst Andy Hargreaves downgraded Cardlytics to Sector Weight, saying its Q2 results showed "solid momentum" in both MAU and ARPU even though the FY19 outlook was disappointing. The analyst notes that the stock still has "excellent" growth potential, but sees the recent appreciation in the stock price and the reduction in forecasts weighing on its risk/reward.
08/09/19
RHCO
08/09/19
NO CHANGE
Target $35
RHCO
Buy
Cardlytics price target raised to $35 from $25 at SunTrust
SunTrust analyst Youssef Squali raised his price target on Cardlytics to $35 and kept his Buy rating after its "solid" Q2 results. The analyst says the company is making strides in creating a digital marketing platform "at scale" and with "mass appeal" with over 120M monthly active users.
08/09/19
08/09/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Maximus (MMS) downgraded to Market Perform from Outperform at Wells Fargo. 2. Cardlytics (CDLX) downgraded to Sector Weight from Overweight at KeyBanc with analyst Andy Hargreaves saying its Q2 results showed "solid momentum" in both MAU and ARPU even though the FY19 outlook was disappointing. 3. Coeur Mining (CDE) downgraded to Hold from Buy at Canaccord. 4. Kraft Heinz (KHC) downgraded to Sell from Neutral at Guggenheim with analyst Laurent Grandet saying the "new negative news" from yesterday's results is that the situation won't likely start to improve until next year at the earliest since new CEO Miguel Patricio's plan won't be implemented until early 2020. 5. Synaptics (SYNA) downgraded to Underweight from Neutral at JPMorgan and to Hold from Buy at Craig-Hallum. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TWOU 2U
$22.58

0.77 (3.53%)

08/08/19
SBSH
08/08/19
INITIATION
Target $20
SBSH
Buy
2U reinstated with a Buy at Citi
Citi analyst Thomas Singlehurst reinstated coverage of 2U with a Buy rating and $20 price target. Although the past few months "have been brutal," the market has overreacted, Singlehurst tells investors in a research note. The analyst believes the company's long-term opportunity remains "very significant."
08/12/19
WBLR
08/12/19
INITIATION
WBLR
Market Perform
2U initiated with a Market Perform at William Blair
William Blair analyst Stephen Sheldon initiated 2U with a Market Perform rating.
08/13/19
WBLR
08/13/19
INITIATION
WBLR
William Blair starts Chegg, K12 with Outperform ratings
William Blair analyst Stephen Sheldon yesterday afternoon initiated coverage of Chegg (CHGG) and K12 (LRN) with Outperform ratings, and of 2U (TWOU) with a Market Perform rating. The analyst also assumed coverage of Instructure (INST) with a Market Perform rating following an analyst departure earlier this year. The amount spent annually on traditional education is large and growing, estimated to reach close to $1.5 trillion in the United States, Sheldon wrote in a research note. There are "numerous pain points" in the education industry, and solutions from education technology providers are helping alleviate some of these "highly complex" issues, adds the analyst. He believes that Chegg should be able to deliver at least 20% revenue growth over the next three years and that K12 can deliver mid-single-digit revenue growth over time. For 2U, Sheldon believes tge shares will be range-bound until the company provides clarity on its long-term model and "rebuilds trust."
10/17/19
DADA
10/17/19
NO CHANGE
Target $17
DADA
Neutral
2U price target lowered to $17 from $27 at DA Davidson
DA Davidson analyst Rishi Jaluria lowered his price target on 2U to $17 and kept his Neutral rating after the company's announcement of a CFO change yesterday. The analyst notes that the incoming CFO Paul Lalljie was the CFO of Neustar which had been taken private by a private equity group and also served as an investment adviser for a number of PE firms, suggesting that 2U may be considering strategic alternatives in the near future. Given the "lack of predictability" in his model and the ongoing headwinds for the company, Jaluria believes that its current 1.4-times enterprise value to expected 2020 revenue multiple that also reflects his new price target is appropriate.
OPNT Opiant Pharmaceuticals
$15.95

0.18 (1.14%)

03/22/19
CANT
03/22/19
NO CHANGE
Target $38
CANT
Overweight
Opiant pipeline remains free at current share levels, says Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes reiterates an Overweight rating on Opiant Pharmaceuticals with a $38 price target following the company's Q4 results. The company is developing treatments focused on multiple addictions, including a potential longer-lasting product for opioid overdose, Folkes tells investors in a research note. He continues to believe Opiant "remains significantly undervalued at current levels." The company's ability to successfully develop products targeting addiction and overdose has been validated by the approval of Narcan nasal spray in 2015. Further, investors are getting the pipeline for free at current share levels, says the analyst.
05/29/19
NORL
05/29/19
INITIATION
Target $42
NORL
Outperform
Opiant Pharmaceuticals initiated with an Outperform at Northland
Northland analyst Carl Byrnes initiated Opiant Pharmaceuticals with an Outperform and $42 price target given its established track record developing NARCAN for opioid overdose. Byrnes believes Opiant's valuation "woefully" understates the company's extensive pipeline, NARCAN royalty stream, government-based funding of key programs, and cash.
DDOG Datadog
$34.40

0.89 (2.66%)

10/14/19
10/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ping Identity (PING) initiated with an Outperform at Wells Fargo, Raymond James, Oppenheimer, Raymond James, RBC Capital, and William Blair, an Overweight at Barclays, as well as a Buy at Mizuho, Citi, BofA/Merrill, Goldman Sachs, Stifel, and Deutsche Bank. 2. Envista (NVST) initiated with an Outperform at Evercore ISI, an Overweight at JPMorgan, a Buy at Jefferies, Goldman Sachs, and Stifel, an Equal Weight at Morgan Stanley, as well as a Neutral at Credit Suisse and BofA/Merrill. 3. Datadog (DDOG) initiated with an Outperform at William Blair, an Overweight at JPMorgan and Barclays, a Buy at Stifel and Needham, an Equal Weight at Morgan Stanley, a Sector Perform at RBC Capital, a Market Perform at Raymond James and JMP Securities, a Neutral at Goldman Sachs, and a Hold at Jefferies. 4. Beyond Meat (BYND) initiated with a Market Perform on valuation at Wells Fargo. 5. Bloom Energy (BE) assumed with an Overweight at KeyBanc. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/19
MSCO
10/24/19
NO CHANGE
MSCO
Morgan Stanley says Datadog has best setup in infrastructure software
Morgan Stanley analyst Sanjit Singh said the infrastructure software market's "state of flux," combined with renewed worries on the spending environment, has resulted in several in the space underperforming the market year-to-date, including New Relic (NEWR), Pivotal (PVTL), Cloudera (CLDR) and PagerDuty (PD). Heading into 3Q reports from the group, he sees Datadog (DDOG) having the most business momentum and best quarterly setup and views it as one of the few in the space that can accelerate growth on a year-over-year basis, Singh said in his earnings preview for the group. While he is looking for Datadog to "highlight its leadership status" in its first quarterly report as a public company, Singh maintains an Equal Weight rating and $39 price target on the stock.
11/06/19
FBCO
11/06/19
INITIATION
Target $40
FBCO
Neutral
Datadog initiated with a Neutral at Credit Suisse
Credit Suisse initiated coverage of Datadog with a Neutral rating and $40 price target.
11/06/19
FBCO
11/06/19
INITIATION
Target $40
FBCO
Neutral
Datadog initiated with a Neutral at Credit Suisse on valuation
Credit Suisse analyst Brad Zelnick initiated coverage of Datadog with a Neutral rating and $40 price target, citing valuation vs. peers and the competitive nature of the market. In a research note to investors, Zelnick says he expects AI and ML capabilities to increasingly become core part of offerings and, given the vast amount of data Datadog's platform already collects, he feels it is well positioned to continue to take share, driving confidence in his 46% top-line CAGR through 2021.
PTE PolarityTE
$2.89

-0.41 (-12.42%)

08/09/19
OPCO
08/09/19
NO CHANGE
Target $14
OPCO
Outperform
PolarityTE price target lowered to $14 from $24 at Oppenheimer
Oppenheimer analyst Kevin DeGeeter lowered his price target for PolarityTE to $14 from $24 and maintained an Outperform rating following the company's second quarter results. In a research note to investors, DeGeeter says he believes new management was effective in providing better transparency on metrics of commercial uptake of SkinTE, rationale for a more targeted sales effort in acute and chronic wounds and a timeline for re-engaging the burn market.
08/20/19
CANT
08/20/19
NO CHANGE
Target $50
CANT
Overweight
PolarityTE's patent approval increases probability of patent protection, says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros notes that PolarityTE was granted a patent by the Canadian Intellectual Property Office related to methods for development and use of minimally polarized function cell micro-aggregate units. The analyst believes that having received the first patent approval, and maintaining a record with no abandoned or lapsed patents, increases the probability of receiving patent protection in other markets. Piros feels confident that direct competition is not a threat at this time given the trade secrets in place for PolarityTE's unique platform. Additionally, the analyst highlights that since creating the Office of the Chief Executive in June, the company has accomplished a number of significant milestones, and he expects more important updates to occur in the second half of 2019. Piros reiterates an Overweight rating and $50 price target on the shares.
09/23/19
CANT
09/23/19
NO CHANGE
Target $50
CANT
Overweight
Cantor 'enthusiastic' about changes taking place at PolarityTE
Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating on PolarityTE with $50 12-month price target after the company over the weekend presented 15 patient case studies of SkinTE during the podium presentation at the American Society of Plastic Surgeons' scientific meeting. The analyst feels "enthusiastic" about the changes PolarityTE has made over the last six months. Although its quarterly reports with revenue updates will be the key focus for investors in the near term, "positive trends" could come forward with the "newly formed, highly experienced" sales and marketing teams as well as the support of current management, Piros tells investors in a research note.
11/11/19
CANT
11/11/19
INITIATION
Target $13
CANT
Overweight
Cantor assumes PolarityTE at Overweight, cuts target to $13 from $50
Cantor Fitzgerald analyst Kristen Kluska assumed coverage of PolarityTE and kept an Overweight rating on the shares with a price target of $13, down from the firm's prior target to $50. The stock closed Friday up 32c to $3.31. Kluska lowered the company's peak revenue estimate to $500M from $1.2B in 2032. Expectations are now lower for SkinTE, and as a result, the setup for shares is better for quarterly revenues over the next 12 months, Kluska tells investors in a research note titled "A Current Valuation That Truly Gets Under the Skin." She believes clinical data from three trials next year, head-to-head burn, diabetic foot ulcers and venous leg ulcers, should be positive and could lead to increased awareness and adoption in near term.
ADPT Adaptive Biotechnologies
$28.35

0.01 (0.04%)

07/22/19
GUGG
07/22/19
INITIATION
Target $47
GUGG
Buy
Adaptive Biotechnologies initiated with a Buy at Guggenheim
Guggenheim analyst David Westenberg initiated Adaptive Biotechnologies with a Buy and $47 price target.
07/22/19
WBLR
07/22/19
INITIATION
WBLR
Outperform
Adaptive Biotechnologies initiated with an Outperform at William Blair
William Blair analyst Brian Weinstein started Adaptive Biotechnologies with an Outperform rating saying the company's technology holds the promise to enable researchers, commercial partners, and ultimately clinicians to better diagnose and treat disease. The analyst sees potential for upside to revenue targets.
07/23/19
BTIG
07/23/19
INITIATION
Target $46
BTIG
Buy
Adaptive Biotechnologies initiated with a Buy at BTIG
BTIG analyst Amanda Murphy initiated Adaptive Biotechnologies (ADPT) with a Buy rating and a price target of $46, saying the company's "clinical immunomics database" represents its "differentiating asset" and offers "incredible value" to biopharma companies. The analyst further cites Adaptive Biotechnologies' partnership with Roche (RHHBY) that should allow it to develop new diagnostics for early detection of diseases where antigens are unknown and also its "strategic" deal with Microsoft (MSFT), whose machine learning capabilities support its immune medicine platform.
07/23/19
07/23/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with a Buy at Rosenblatt, while Twitter (TWTR) was initiated with a Neutral. 2. Silicon Labs (SLAB) initiated with a Buy at Benchmark, while Intel (INTC) and Xilinx (XLNX) were initiated with Hold ratings. 3. Cambridge Bancorp (CATC) initiated with a Market Perform at Keefe Bruyette. 4. Broadcom (AVGO) assumed with an Outperform at RBC Capital. 5. Adaptive Biotechnologies (ADPT) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ADT ADT Inc.
$7.70

-0.02 (-0.26%)

03/12/19
SBSH
03/12/19
DOWNGRADE
Target $8.25
SBSH
Neutral
ADT Inc. downgraded to Neutral from Buy at Citi
Cit downgraded ADT Inc. to Neutral from Buy and lowered its price target for the shares to $8.25 from $13. The firm sees a less certain free cash flow trajectory following ADT's Q4 results.
03/15/19
IMPC
03/15/19
NO CHANGE
Target $12
IMPC
Outperform
ADT Inc. price target lowered to $12 from $15 at Imperial Capital
Imperial Capital analyst Jeff Kessler lowered his price target for ADT Inc. to $12 from $15 saying "heavy" investment translated to reduced free cash flow guidance for 2019. The analyst, however, sees continued revenue growth for ADT and maintains an Outperform rating on the shares.
05/13/19
MSCO
05/13/19
DOWNGRADE
Target $7
MSCO
Equal Weight
ADT Inc. downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Toni Kaplan downgraded ADT Inc. (ADT) to Equal Weight from Overweight as she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. The survey showed homeowners seem as inclined to buy DIY systems as ADT systems, that more ADT customers switched to DIY providers than she would have expected and that measure of brand preference for Amazon's (AMZN) Ring and Google's (GOOG) Nest were higher than for ADT, Kaplan explains. Given that the survey leads her to fear ADT may find it difficult to defend its market share, Kaplan lowered her price target on the stock to $7 from $9.
05/13/19
05/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Deere (DE) and Titan Machinery (TITN) downgraded to Neutral from Outperform at Baird. 2. Boot Barn (BOOT) downgraded to Hold from Buy at Pivotal Research with analyst Mitch Kummetz saying he sees a less favorable risk/reward at current share levels heading into the company's results on May 16. He does not see enough room for upside to his estimates, mainly because he believes oil and gas employment is becoming a "diminishing tailwind." 3. Shopify (SHOP) downgraded to Neutral from Buy at Guggenheim with analyst Ken Wong saying he sees upside potential as limited given the stock's current valuation, which he notes has now passed previous peak levels. 4. ADT Inc. (ADT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Toni Kaplan saying she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. 5. 51job (JOBS) downgraded to Neutral from Buy at Citi with analyst Alicia Yap saying she believes weakening operating metrics, such as a faster rate of decline for active employer count and slower rate of growth of ARPU, may be signals of challenges for online recruitment revenue growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BDSI BioDelivery Sciences
$5.86

0.02 (0.34%)

01/31/19
01/31/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. At Home Group (HOME) initiated with a Hold at Gordon Haskett. 2. Teladoc (TDOC) initiated with a Buy at Berenberg. 3. Intercept (ICPT) initiated with an Outperform at Credit Suisse. 4. Recro Pharma (REPH), BioDelivery Sciences (BDSI), and Supernus (SUPN) were assumed with a Buy at Janney Montgomery Scott. 5. Green Thumb Industries (GTBIF) initiated with a Buy at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/19/19
RHCO
03/19/19
INITIATION
Target $7
RHCO
Buy
BioDelivery Sciences initiated with a Buy at SunTrust
SunTrust analyst Gregg Gilbert started BioDelivery Sciences with a Buy rating and $7 price target. The company is well positioned to drive continued adoption of Belbuca in the "large" long-acting opioid market, giving management more flexibility to explore options to diversify the business and enhance value, says the analyst.
04/16/19
CANT
04/16/19
NO CHANGE
Target $8
CANT
Overweight
BioDelivery acquisitoin of Symproic a positive, says Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes views BioDelivery Sciences' acquisition of Symproic as a positive saying it diversifies the company's revenue away from a single product, Belbuca, and can add a "meaningful "revenue contribution of $75M-plus "without the need for any significant increase in spending." The acquisition is a positive step towards building a "significantly" larger company, focusing on pain, and the complications around pain treatment, Folkes tells investors in a research note. He reiterates an Overweight rating on the shares with an $8 price target.
09/17/19
WBLR
09/17/19
NO CHANGE
WBLR
Outperform
Purdue bankruptcy positive for Collegium and BioDelivery, says William Blair
William Blair analyst Tim Lugo views the bankruptcy of Purdue Pharma as positive for Collegium Pharmaceutical (COLL). Purdue's preliminary agreement for settling its opioid litigation and filing for Chapter 11 bankruptcy will significantly benefit companies that promote the responsible use of opioids for pain management such as Collegium and BioDelivery Sciences (BDSI," Lugo tells investors in a research note. Purdue's most widely known product was OxyContin, an extended release formulation of oxycodone that had a strong hold on the oxycodone market share, says the analyst. He believes OxyContin's market share will "significantly deteriorate" after Purdue's bankruptcy, driving prescribers to use products such as Collegium's Xtampza ER, an extended release abuse-deterrent formulation of oxycodone. Lugo keeps Outperform ratings on both Collegium and BioDelivery.
AQMS Aqua Metals
$1.45

-0.065 (-4.29%)

05/15/19
OPCO
05/15/19
NO CHANGE
Target $9
OPCO
Outperform
Aqua Metals price target lowered to $9 from $14 at Oppenheimer
Oppenheimer analyst Colin Rusch lowered his price target for Aqua Metals to $9 from $14 on increased share count, higher operating expenses and a slower revenue ramp as it shifts to equipment and licensing revenue for growth. The analyst notes that the company posted a wider than expected loss for the quarter while shoring up the balance sheet with an equity raise. He reiterates an Outperform rating on the shares.
YY YY
$65.12

-0.28 (-0.43%)

07/15/19
NOMU
07/15/19
NO CHANGE
Target $79
NOMU
Buy
YY target raised to $79 ahead of Q2 results at Nomura Instinet
Nomura Instinet analyst Jialong Shi raised his price target for YY to $79 from $77 ahead of the company's Q2 results and keeps a Buy rating on the shares. The analyst forecasts YY's consolidated revenue in Q2 will grow 64% year-over-year and 1% above consensus on the back of the strong growth in Huya and a full quarter consolidation of Bigo.
08/05/19
JEFF
08/05/19
INITIATION
Target $76.1
JEFF
Buy
YY initiated with a Buy at Jefferies
Jefferies analyst Thomas Chong initiated YY with a Buy rating and $76.10 price target, noting that it is one of the few internet companies in China stepping up overseas expansion in 2019, which he views as a positive for long-term growth. He also notes that YY's product portfolio has "a huge user base" of over 400M users with solid growth across different applications.
09/20/19
UBSW
09/20/19
UPGRADE
UBSW
Buy
YY upgraded to Buy from Neutral at UBS
09/20/19
UBSW
09/20/19
UPGRADE
UBSW
Buy
YY upgraded to Buy from Neutral at UBS
UBS analyst Jerry Liu upgraded YY to Buy from Neutral, stating that he thinks the market is too pessimistic about YY Live, its showroom live streaming business in China, and Bigo, the company's international live streaming, short-video and social-networking business. He thinks a deceleration in showroom growth is more likely than an extreme decline in growth and margins, said Liu.
HUYA Huya
$24.28

-1.05 (-4.15%)

08/05/19
JEFF
08/05/19
INITIATION
Target $26.8
JEFF
Buy
Huya initiated with a Buy at Jefferies
Jefferies analyst Thomas Chong started Huya with a Buy rating and $26.80 price target. The analyst expects Huya to "ride on the increasing popularity" of e-Sports in China with "fast" revenue growth amid the early stages of game broadcasting monetization in China.
08/14/19
DAIW
08/14/19
UPGRADE
DAIW
Buy
Huya upgraded to Buy from Outperform at Daiwa
08/14/19
LYON
08/14/19
UPGRADE
LYON
Buy
Huya upgraded to Buy from Outperform at CLSA
09/16/19
HSBC
09/16/19
INITIATION
Target $30.1
HSBC
Buy
Huya initiated with a Buy at HSBC
HSBC analyst Binnie Wong started Huya with a Buy rating and $30.10 price target. The company has a proven record of profitability due to better operating efficiency and effective leverage of streaming agencies, Wong tells investors in a research note. She believes Huya's premium valuation is justified by its better earnings visibility.
RUN Sunrun
$14.49

0.08 (0.56%)

08/19/19
KEYB
08/19/19
INITIATION
Target $19
KEYB
Overweight
Sunrun initiated with an Overweight at KeyBanc
KeyBanc analyst Sophie Karp initiated Sunrun with an Overweight rating and $19 price target.
08/20/19
08/20/19
INITIATION
Target $19

Overweight
KeyBanc bullish on Sunrun, initiates with an Overweight
As previously reported, KeyBanc analyst Sophie Karp initiated Sunrun with an Overweight rating and $19 price target as she believes it offers the best growth prospects. The analyst argues that Sunrun is the "most efficient" capital recycler in the space and has distinguished itself with "significant cost discipline and sagacious financial execution." Given the company's scale, Karp thinks it is best positioned to monetize its R&D investments to eventually develop additional revenue streams from grid services/"virtual power plants," with which the company has been experimenting.
08/20/19
08/20/19
INITIATION
Target $13

Overweight
KeyBanc bullish on Sunnova Energy, initiates with an Overweight
As previously reported, KeyBanc analyst Sophie Karp initiated Sunnova Energy (NOVA) with an Overweight and $13 price target. The analyst notes that shares of Sunnova lie somewhere in between Vivint Solar (VSLR) and Sunrun (RUN) in terms of the margin of safety, since the net value of Sunnova's existing portfolio of assets amounts to about $9/share. Karp believes Sunnova boasts the most significant operating leverage owing to its dealer-only operating model, and expects it to grow aggressively in the 2019-2020 time-frame.
08/20/19
08/20/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Immunomedics (IMMU) initiated with an Overweight at Cantor Fitzgerald. 2. PayPal (PYPL) initiated with a Buy at Rosenblatt while Square (SQ) was initiated with a Neutral. 3. Sunrun (RUN), Vivint Solar (VSLR), and Sunnova Energy (NOVA) initiated with an Overweight at KeyBanc. 4. Spotify (SPOT) initiated with an Equal Weight at Consumer Edge. 5. Silk Road Medical (SILK) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
VRAY ViewRay
$2.48

-0.145 (-5.53%)

09/16/19
PIPR
09/16/19
NO CHANGE
Target $6
PIPR
Overweight
ViewRay recent orders 'incremental positives,' says Piper Jaffray
ViewRay this morning announced that Penn State Health has entered a master agreement to purchase up to four MRIdian systems with the immediate order of one system and the ability to order an additional three systems in the future, Piper Jaffray analyst Matt O'Brien tells investors in a research note. This news follows an announcement last Thursday of an MRIdian order from Stanford Health Care, adds the analyst. He views these orders as "incremental positives" and further evidence of the "unique capabilities" of the MRIdian system. O'Brien reiterates an Overweight rating on ViewRay with a $6 price target.
10/15/19
PIPR
10/15/19
NO CHANGE
Target $6
PIPR
Overweight
ViewRay preannounced better than expected Q3, says Piper Jaffray
ViewRay this morning preannounced better than expected Q3 sales results after installing three systems compared to the Street estimate at two, Piper Jaffray analyst Matt O'Brien tells investors in a research note. Further, the eight MRIdian system orders in Q3, including three upgrades, were in-line with expectations and a "welcome sight" as investors had worried that hesitancy around the proposed reimbursement bundle would result in significant delays in purchasing decisions, adds the analyst. He views the results as "largely positive" and reiterates an Overweight rating on ViewRay shares with a $6 price target. O'Brien, who admits the company's cash burn was a little higher than he had modeled, sees a "compelling entry point" at current ViewRay share levels.
10/21/19
OPCO
10/21/19
INITIATION
Target $7
OPCO
Outperform
ViewRay initiated with an Outperform at Oppenheimer
Oppenheimer analyst Suraj Kalia initiated coverage of ViewRay with an Outperform rating and $7 price target.
10/21/19
OPCO
10/21/19
INITIATION
Target $7
OPCO
Outperform
Oppenheimer starts ViewRay with Outperform rating, $7 price target
Oppenheimer analyst Suraj Kalia initiated coverage of ViewRay with an Outperform rating and $7 price target. The promise of ViewRay's technology is in superior outcomes and lower toxicity, says Kalia, who estimates that 20%-30% of all medical linear accelerators placed within ten years will have magnetic resonance-guided capabilities. "We are in the first innings of a highly disruptive technology adoption curve," Kalia tells investors in a research note.
DZSI Dasan Zhone
$8.34

0.5 (6.38%)

05/20/19
RILY
05/20/19
INITIATION
Target $19.5
RILY
Buy
Dasan Zhone initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Dave Kang started Dasan Zhone Solutions with a Buy rating and $19.50 price target. The company is outpacing the broadband industry through share gains, Kang tells investors in a research note.
07/09/19
RILY
07/09/19
NO CHANGE
RILY
B. Riley FBR says China supply chain internalization issue for optical industry
B. Riley FBR analyst Dave Kang lowered his price target for Lumentum (LITE) to $68 from $74 and for Inphi (IPHI) to $45 from $47. While the ban on Huawei has garnered investor attention recently, the bigger issue for the optical industry could be China's internalization of its supply chain, which has been accelerated due to the recent ban, Kang tells investors in a research note. The analyst believes that even after the partial reprieve on Huawei, the U.S. optical companies may not fully recover to the previous levels with Huawei. Recent channel checks revealed that Huawei has significantly accelerated the internalization process of its supply chain, adds the analyst. As a result, he believes the U.S. optical industry is facing "collateral damage" from the trade war with China. Kang keeps a Buy rating on Lumentum and Neutral rating on Inphi. He favors Huawei's competitors such as Ciena (CIEN) and Dasan Zhone Solutions (DZSI), which he believes could gain market share from international customers diversifying away from Huawei.
10/08/19
NORL
10/08/19
NO CHANGE
Target $15.5
NORL
Outperform
Dasan Zhone price target lowered to $15.50 from $20.00 at Northland
Northland analyst Tim Savageaux cut his price target on Dasan Zhone Solutions to $15.50 from $20.00 after the company pre-announced significantly lower than expected Q3 revenues, which it blamed on "recent industry wide trends in reduced carrier spend combined with temporary postponements in capital spending for Fiber-to-the-Home project at selected DZS customers." Given Dasan's focus on early 5G rollout markets, recent wins in Japan and limited customer concentration, he is surprised at the degree of impact from the FTTH weakness, said Savageaux, who keeps an Outperform rating on the stock.
HIIQ Health Insurance Innovations
$23.27

-1.71 (-6.85%)

08/13/19
CANT
08/13/19
NO CHANGE
Target $80
CANT
Overweight
Health Insurance cash flow not major concern, says Cantor Fitzgerald
After reviewing Health Insurance Innovations' cash flow during the first half of 2019, Cantor Fitzgerald analyst Steven Halper is not that concerned about the company's use of cash. Excluding different items, the company generated free cash flow over the trailing 12 months, which makes the reported negative cash flow not a major concern, Halper tells investors in a research note. Looking ahead, it is entirely possible that Health Insurance will continue to use cash as it begins to build up its Medicare business, adds the analyst. However, he remains optimistic about its Medicare initiative, which he believes should enhance its valuation over time. Halper reiterates an Overweight rating on Health Insurance Innovations with an $80 price target.
08/16/19
PIPR
08/16/19
NO CHANGE
Target $87
PIPR
Overweight
Teladoc short report selloff brings buying opportunity, says Piper Jaffray
Shares of Teladoc Health (TDOC) fell yesterday after a short report raised questions about the company's relationship with Health Insurance Innovations (HIIQ), Piper Jaffray analyst Sean Wieland tells investors in a research note. After speaking with Teladoc's CFO, the analyst believes the "drama is unwarranted," and he encourages investors to take advantage of "another buying opportunity." The CFO told Wieland that Health Insurance is a client of Teladoc under the "visits included" model, which means neither Health Insurance nor the member pay a fee each time the service is used. According to Teladoc, less than 1% of revenue and EBITDA is tied to Health Insurance Innovations, Wieland tells investors in a research note. He believes the short report is "flawed because it relies on inaccurate assumptions and slippery-slope logic." Wieland reiterates an Overweight rating on Teladoc with an $87 price target. The stock closed yesterday down 7.5%, or $4.56, to $56.94.
09/20/19
09/20/19
NO CHANGE

Health Insurance Innovations management to meet with B. Riley FBR
Meeting to be held in San Francisco, CA on September 20 hosted by B. Riley FBR.
09/25/19
RILY
09/25/19
NO CHANGE
Target $45
RILY
Buy
Health Insurance should be bought on yesterday's selloff, says B. Riley FBR
The Centers for Medicare and Medicaid Services announced yesterday in a press release its prediction of a ~10% increase in Medicare Advantage enrollment for the 2020 open-enrollment period, which is November 1 to December 15, B. Riley FBR analyst Randy Binner tells investors in a research note. At the same time, CMS predicted an average 23% decline in Medicare Advantage premiums expected to be paid by consumers, the analyst points out. He believes the market misinterpreted the announcement, causing Heath Insurance Innovations (HIIQ) and eHealth (EHTH) to trade lower. eHealth is a well-established distributor of Medicare Advantage products, and Heath Insurance Innovations is pivoting its strategy to have MA and similar products comprise a larger share of its overall production in the second half of 2019, explains Binner. He believes a larger, predicted volume of MA contracts should be positive for distributors like Heath Insurance and eHealth. As such the analyst recommends using yesterday's selloff in Heath Insurance Innovations as a buying opportunity. He reiterates a Buy rating on the shares with a $45 price target.
CBPX Continental Building
$35.76

3.73 (11.65%)

04/17/19
RBCM
04/17/19
DOWNGRADE
RBCM
Sector Perform
Continental Building downgraded to Sector Perform at RBC Capital
04/17/19
04/17/19
DOWNGRADE
Target $26

Sector Perform
Continental Building cut to Sector Perform at RBC Capital on weaker pricing
As previously reported, RBC Capital analyst Mike Dahl downgraded Continental Building to Sector Perform from Outperform and lowered his price target to $26 from $30, citing his "weaker wallboard pricing expectations". The analyst points to the latest round of producer price index data suggesting that the price of Wallboard fell by 3% from last quarter and 5% from last year during Q1, even though the company announced a 12% price increase while competing Wallboard OEM's had announced price increases in the 12%-18% range. Dahl also attributes the downgrade to "increased industry capacity, a subdued demand environment still suffering from 2018 housing weakness and diminished cost pressures."
06/14/19
LBOW
06/14/19
NO CHANGE
LBOW
Neutral
Eagle Materials, Continental Building estimates lowered after survey at Longbow
Longbow analyst Garik Shmois said his wallboard survey pointed to mid-single digit demand declines from OEMs along with continued weakness in prices. Following the survey, he lowered his estimates for both Eagle Materials (EXP) and Continental Building (CBPX), on which he keeps Neutral ratings.
10/09/19
EXAN
10/09/19
INITIATION
EXAN
Outperform
Continental Building initiated with an Outperform rating at Exane BNP Paribas
KNSL Kinsale Capital Group
$88.98

1.78 (2.04%)

02/25/19
RHCO
02/25/19
NO CHANGE
Target $75
RHCO
Buy
Kinsale Capital Group price target raised to $75 from $66 at SunTrust
SunTrust analyst Mark Hughes raised his price target on Kinsale Capital Group to $75 and kept his Buy rating after its Q4 earnings beat, also raising his FY19 EPS view to $2.24 from $2.10. The analyst cites the company's "continuing acceleration" in revenue growth and further opportunity in the E&S market, saying it is an "attractive stock" for investors in search of high quality financials. Hughes further notes that he assumes a 13% gross written premium growth this year in his model but also believes that these figures could "prove conservative in light of the robust submission activity at the company and favorable industry dynamics."
07/01/19
RHCO
07/01/19
NO CHANGE
Target $100
RHCO
Buy
Kinsale Capital Group price target raised to $100 from $85 at SunTrust
SunTrust analyst Mark Hughes raised his price target for Kinsale Capital Group to $100 from $85 and maintained a Buy rating following a trip with CEO Mike Kehoe to visit investors in Detroit and Southern California. In a research note to investors, Hughes says there was considerable discussion around sustainability of growth, as well as the stock valuation.
09/06/19
JMPS
09/06/19
INITIATION
JMPS
Market Perform
Kinsale Capital Group initiated with a Market Perform at JMP Securities
JMP Securities analyst Matthew Carletti initiated Kinsale Capital Group with a Market Perform rating, saying its excess & surplus lines, or E&S, insurance is in a market that is experiencing "significant growth and strong pricing increases in response to recent turmoil". The analyst points to the company's "best-in-class combined ratios and ROEs" and anticipates continued attractive growth opportunities, but also notes its premium valuation, with the stock trading at 7.1-times book value vs. the peer group average multiple of 2.5-times.
09/26/19
UBSW
09/26/19
NO CHANGE
Target $112
UBSW
Buy
Kinsale Capital Group price target raised to $112 from $98 at UBS
UBS analyst Mark Dwelle raised his price target on Kinsale Capital Group to $112 and kept his Buy rating after holding meetings with its management. The analyst says the tone of the discussions was positive, reflecting the company's confidence in delivering combined ratios in mid-80s and ROE of 15%. Dwelle adds that most of Kinsale's "broad based growth" has been "organic new business" supported by the 20% increase in submissions.
BOXL Boxlight
$1.94

0.19 (10.86%)

04/10/19
MAXM
04/10/19
INITIATION
Target $11
MAXM
Buy
Boxlight initiated with a Buy at Maxim
Maxim analyst Allen Klee initiated Boxlight with a Buy rating and a price target of $11, saying the company is "providing a 'smart' approach to modernizing education". The analyst anticipates Boxlight to generate 25% or more in organic growth over the next 3 years with upside from acquisitions, which he states have improved the company's product breadth as well as "expanded international presence, broadened the reseller network, and shifted the mix to higher-margin offerings."
10/22/19
NATL
10/22/19
INITIATION
Target $4
NATL
Buy
Boxlight initiated with a Buy at National Securities
National Securities initiated coverage of Boxlight with a Buy rating and $4 price target.
SSTI ShotSpotter
$20.36

(0.00%)

08/06/19
WBLR
08/06/19
DOWNGRADE
WBLR
Market Perform
ShotSpotter downgraded to Market Perform from Outperform at William Blair
William Blair analyst Matthew Pfau downgraded ShotSpotter to Market Perform from Outperform citing the company's fiscal 2019 guidance reduction on contract timing.
08/07/19
LSCM
08/07/19
NO CHANGE
Target $40
LSCM
Buy
ShotSpotter price target lowered to $40 from $50 at Lake Street
Lake Street analyst Jaeson Schmidt lowered his price target for ShotSpotter to $40 from $50 after the company reduced its guidance to reflect the timing of contracts. While the magnitude of the downward adjustment is relatively small, the stock is likely to sell off sharply as this is the second consecutive ShotSpotter lowered its outlook and fuels concern in a more severe deceleration in growth, Schmidt tells investors in a research note. The analyst, however, maintains a Buy rating on the shares.
09/27/19
RILY
09/27/19
NO CHANGE
Target $50
RILY
Buy
ShotSpotter removed from Alpha Generator list at B. Riley FBR
B. Riley FBR analyst Christopher Van Horn lowered his price target for ShotSpotter to $50 from $59 and removed the shares from his firm's Alpha Generator list. The company has lowered their guidance over the past two quarters mainly due to the potential timing of new awards, Van Horn tells investors in a research note. The analyst, who continues to recognize that the "guidance reductions are challenging," remains bullish on shares of ShotSpotter. The timing for ShotSpotter's technology "can be lumpy" and the business that is delayed is likely to show up in 2020 and later in 2019, contends Van Horn. He reiterates a Buy rating on the name.
10/18/19
IMPC
10/18/19
NO CHANGE
Target $38
IMPC
Outperform
ShotSpotter price target lowered to $38 from $48 at Imperial Capital
Imperial Capital analyst Jeff Kessler lowered his price target for ShotSpotter to $38 from $48 saying the company's international pipeline is being lengthened by the regulatory process in different countries. The analyst, however, remains "relatively positive" on ShotSpotter's growth prospects and keeps an Outperform rating on the shares ahead of its Q3 results.
TVTY Tivity Health
$18.56

0.145 (0.79%)

05/09/19
OPCO
05/09/19
NO CHANGE
Target $36
OPCO
Outperform
Tivity Health price target raised to $36 from $31 at Oppenheimer
Oppenheimer analyst Mohan Naidu raised his price target for Tivity Health to $36 from $31 after the company reported better than expected numbers in both Healthcare and Nutrition segments. Positive results in the quarter, stabilizing Nutrisystem segment and increasing confidence in the cross-sell into health plans should improve investor sentiment, he contends. The analyst reiterates an Outperform rating on the shares.
08/08/19
PIPR
08/08/19
NO CHANGE
Target $25
PIPR
Overweight
Tivity Health price target lowered to $25 from $33 at Piper Jaffray
Piper Jaffray analyst Sean Wieland lowered his price target for Tivity Health to $25 from $33 after the company lowered guidance for its nutrition business due to a decline in new client starts. However, the healthcare business is "going great," Wieland tells investors in a research note. While he lowered his estimates for Tivity Health he reiterates an Overweight rating on the shares.
08/08/19
BRRR
08/08/19
NO CHANGE
Target $40
BRRR
Outperform
Tivity Health shares offer over 100% upside potential, says Barrington
Shares of Tivity Health "simply seem way too cheap" at current levels, especially after the company gave a "positive" update for its healthcare business through at least fiscal 2020, Barrington analyst Michael Petusky tells investors in a research note. While Tivity reduced expectations for its nutrition business, it provided a bullish outlook for healthcare, says Petusky. The analyst notes his price target of $40 implies over 100% upside from current share levels. He keeps an Outperform rating on Tivity Health.
08/26/19
CANT
08/26/19
NO CHANGE
Target $45
CANT
Overweight
Tivity Health shares remain inexpensive, says Cantor Fitzgerald
After hosting investor meetings with management, Cantor Fitzgerald analyst Steven Halper reiterates an Overweight rating on Tivity Health with a $45 price target. The analyst remains encouraged regarding Tivity's Healthcare segment performance. Further, he believes the company is taking the necessary steps to improve Nutrition performance next year. Halper believes Tivity Health is inexpensive at current share levels.
GEVO Gevo
$2.57

0.065 (2.59%)

CSIQ Canadian Solar
$17.51

0.65 (3.86%)

04/11/19
JPMS
04/11/19
INITIATION
Target $22
JPMS
Neutral
Canadian Solar assumed with a Neutral at JPMorgan
JPMorgan analyst Mark Strouse assumed coverage of Canadian Solar (CSIQ) with a Neutral rating and $22 price target. The rating is unchanged and the target is raised from $21 relative to the firm's prior coverage. The analyst believes Canadian Solar is "approximately fairly valued" pending improved visibility and prefer shares of First Solar (FSLR).
04/11/19
04/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with a Hold at HSBC. 2. Apple (AAPL), Dell Technologies (DELL), and HP Inc. (HPQ) initiated with a Neutral at Credit Suisse. 3. Yeti (YETI) initiated with an Outperform at Cowen. 4. CVS Health (CVS) initiated with a Market Perform at BMO Capital. 5. Canadian Solar (CSIQ) assumed with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/19
ROTH
08/16/19
NO CHANGE
Target $32
ROTH
Buy
Canadian Solar price target raised to $32 from $27 at Roth Capital
Roth Capital analyst Philip Shen reiterated a Buy rating on Canadian Solar and raised his price target to $32 from $27 following the company's "strong" Q2 results. In a research note to investors, Shen says the company is delivering on its outlook for stronger margins and steadily monetizing its global portfolio of operating and late stage assets and sees an upside revision cycle ahead for 2020 estimates. With the backdrop of strong China demand in Q4, Shen expects the stock to move higher.
10/07/19
GSCO
10/07/19
NO CHANGE
GSCO
Goldman says U.S. solar makers should benefit from end of bifacial exemption
Goldman Sachs analyst Brian Lee noted that the Office of the United States Trade Representative said it will withdraw a previously granted Section 201 tariff exemption for bifacial solar panels, which he sees removing a key potential overhang for solar panel pricing and U.S. competition and also believes was unexpected by most investors. Lee thinks U.S. solar manufacturers such as First Solar (FSLR) and SunPower (SPWR) are key beneficiaries of the news, while Chinese solar panel makers with bifacial capacity expansion plans, including JinkoSolar (JKS) and Canadian Solar (CSIQ), are most likely to be negatively impacted. Lee has Buy ratings on First Solar, SunPower and Canadian Solar and a Sell rating on JinkoSolar.
SDC SmileDirectClub
$11.02

-0.83 (-7.00%)

10/15/19
GUGG
10/15/19
NO CHANGE
Target $24
GUGG
Buy
SmileDirectClub should consider pre-announcing Q3 results, says Guggenheim
Guggenheim analyst Glen Santangelo noted that 36 state dental boards have filed some complaint against the practice of teledentistry, so California's AB1519 is "not a new issue" for SmileDirectClub. However, the signing of the new bill into law has aggravated regulatory uncertainty and added to pre-existing near-term concerns about revenues, Santangelo said. Given his view that Q3 results and guidance will be positive data points, and his belief that management's reiteration of its view that the recent legislation passed in California will not disrupt its business model would help alleviate some concerns, Santangelo thinks management should consider pre-announcing Q3 results , though he has "no indication that the company will consider going down this route." Santangelo keeps a Buy rating with a $24 price target on SmileDirectClub shares, though he expects the stock "to languish until the company discloses revenues and reiterates its position on the regulatory uncertainty in a more convincing way."
10/17/19
FBCO
10/17/19
NO CHANGE
FBCO
SmileDirectClub reaction to CA Assembly Bill 1519 overdone, says Credit Suisse
Credit Suisse analyst Erin Wilson Wright said she believes the 13% decline in SmileDirectClub shares on Monday following news that California Assembly Bill 1519 was signed was "overdone," adding that based on her talks today with the company's General Council she does not foresee the company modifying its operations in the state. SmileDirect, which has faced backlash from several other state professional organizations, continues to defend its practices "effectively" and is taking an increasingly more proactive approach, Wilson Wright said. She maintains an Outperform rating on SmileDirectClub shares.
10/23/19
GUGG
10/23/19
NO CHANGE
Target $24
GUGG
Buy
Guggenheim says SmileDirect California situation more unique than first thought
Guggenheim analyst Glen Santangelo said in a note before the open that he has received many questions about California bill AB1519 amid broad assumptions that similar legislation would be enacted across the entire country. However, his deeper dive revealed that the bill, which should have been a routine recertification of the State Dental Board, went through a progression that illustrates more of a unique situation in California than he originally thought existed. He found that the CA Dental Association is the number one campaign contributor to California Assemblyman Evan Low, who authored the bill, and Santangelo noted that Governor Gavin Newsom signed the bill while also voicing in writing his dissatisfaction with the process. The analyst, who concluded that the state may be unique in terms of the prioritization of the dental industry in legislative action, keeps a Buy rating and $24 price target on shares of SmileDirectClub.
10/28/19
JPMS
10/28/19
NO CHANGE
Target $31
JPMS
Overweight
JPMorgan calls SmileDirectClub 'one of the best buying opportunities' it covers
There is a lot of misinformation and confusion around SmileDirectClub's ongoing litigations in states to prevent the introduction of rules that are specifically aimed to prohibit its direct-to-consumer orthodontic practice, JPMorgan analyst Robbie Marcus tells investors in a research note. However, the company is "very well positioned" in the battle against orthodontists and dentists who are being disrupted by the direct-to-consumer model, Marcus tells investors in a research note. Further, the analyst expects "strong" Q3 results when SmileDirectClub reports on November 12. He views the company as "one of the best buying opportunities" in his coverage universe. Marcus keeps an Overweight rating on SmileDirectClub with a $31 price target.
SWKS Skyworks
$101.59

1.22 (1.22%)

10/10/19
10/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) upgraded to Buy from Neutral at Longbow with analyst Shawn Harrison saying his contacts, who previously gave him initial conservative forecasts for up to a 10% year-over-year decline in iPhone production in the calendar third quarter, now see flat production in the period of Apple's fiscal fourth quarter. 2. Qorvo (QRVO) and Skyworks (SWKS) upgraded to Outperform from Market Perform at Cowen. 3. Allegheny Technologies (ATI) upgraded to Buy from Neutral at Goldman Sachs with analyst Matthew Korn saying Allegheny is one of few stocks in the sector with sales growth that does not depend on a commodity price recovery. 4. Bed Bath & Beyond (BBBY) upgraded to Outperform from Market Perform at Telsey Advisory. 5. Morgan Stanley (MS) upgraded to Buy from Hold at Sandler O'Neill with analyst Jeffery Harte citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage click here.
11/01/19
RILY
11/01/19
NO CHANGE
Target $105
RILY
Buy
Skyworks price target raised to $105 from $95 at B. Riley FBR
B. Riley FBR analyst Craig Ellis raised his price target for Skyworks Solutions to $105 from $95 ahead of the company's results on November 12. He believes quarterly execution will be solid overall "despite macro cross currents," helped by better than initially expected iPhone sales in Integrated Mobil and secular strong Broad Markets gains. The analyst expects another "leg up for the shares" over the next 12 months and keeps a Buy rating on Skyworks.
11/11/19
COWN
11/11/19
NO CHANGE
Target $95
COWN
Outperform
Skyworks should see slight upside to Q3 estimates, says Cowen
Cowen analyst Karl Ackerman expects Skyworks to report a slight beat on its Q3 results and believes Street estimates are too low for Q4. The analyst acknowledged expectations are elevated but he sees early signs of progress on WiFi 6 and healthy peer commentary indicating a more promising 2020. Ackerman reiterated his Outperform rating and $95 price target on Skyworks shares.
11/12/19
BMOC
11/12/19
NO CHANGE
Target $120
BMOC
Outperform
Skyworks price target raised to $120 from $100 at BMO Capital
BMO Capital analyst Ambrish Srivastava raised his price target on Skyworks (SWKS) to $120 and kept his Outperform rating ahead of its Q4 earnings today. The analyst notes that while the expectations are already high given the better than expected results at Qorvo (QRVO) and on indications that the 5G handset build is "finally starting to happen", he sees "further upside" for Skyworks stock.
VREX Varex Imaging
$32.68

0.1 (0.31%)

06/11/19
06/11/19
UPGRADE

Varex Imaging upgraded to Market Outperform from Perform at CJS Securities
CJS Securities analyst Lawrence Solow upgraded Varex Imaging to Market Outperform from Perform, citing his expectations for improved performance and a waning impact from tariffs.
09/09/19
09/09/19
NO CHANGE

Varex Imaging management to meet with Sidoti
Meetings to be held in Salt Lake City on September 9 and in Denver, CO on September 10 hosted by Sidoti.
10/21/19
OPCO
10/21/19
INITIATION
Target $40
OPCO
Outperform
Varex Imaging initiated with an Outperform at Oppenheimer
Oppenheimer analyst Suraj Kalia initiated coverage of Varex Imaging with an Outperform rating and $40 price target.
10/21/19
OPCO
10/21/19
INITIATION
Target $40
OPCO
Outperform
Oppenheimer starts Varex Imaging at Outperform with $40 price target
As previously reported, Oppenheimer analyst Suraj Kalia initiated coverage of Varex Imaging with an Outperform rating and $40 price target. The company is a "leading supplier" of x-ray imaging components with a roughly 20% share of a global x-ray imaging market that is $4B and growing at a 3-5% compound annual growth rate, Kalia noted. Switching costs are high, giving the company "stickiness" in its end-user sites, and barriers to entry are also high, the analyst added.
TLRY Tilray
$21.57

-0.4 (-1.82%)

10/25/19
JEFF
10/25/19
NO CHANGE
Target $25
JEFF
Hold
Tilray clinical trial update yesterday a positive, says Jefferies
Tilray yesterday announced that it has successfully imported cannabis into the U.S. from Canada in support of a new clinical trial related to a breast cancer condition, Jefferies analyst Owen Bennett tells investors in a research note. With much of Tilray's future value dependent on delivery in the medical space, this update is a positive, contends the analyst. In addition, with the clinical trial happening in the U.S., "relationships such as this can only support Tilray in supporting US market penetration should it become federally permissible," says Bennett. He believes the news will boost sentiment for Tilray's medical outlook. The analyst keeps a Hold rating on the shares with a $25 price target.
11/04/19
CANT
11/04/19
INITIATION
Target $20
CANT
Neutral
Tilray initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Pablo Zuanic initiated coverage of Tilray with a Neutral rating and $20 price target.
11/05/19
CANT
11/05/19
INITIATION
Target $20
CANT
Neutral
Tilray initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Pablo Zuanic initiated coverage of Tilray with a Neutral rating and $20 price target. The analyst expects the Canadian licenses producer group to rally in the coming months on "more positive than negative catalysts," but he sees more upside in other stocks.
11/05/19
BOFA
11/05/19
NO CHANGE
BOFA
BofA says Mexico cannabis legalization 'still in play' in 2020 after extension
BofA Merrill Lynch analyst Christopher Carey noted that Mexico's Supreme Court has granted an extension until April 30, 2020 for Congress to legalize all forms of cannabis, writing in its decision that considering the complexity of the issue it grants the extension "exceptionally and for one time only." He views this as an important development for the industry since, in addition to opening a potentially large market, it will put even more pressure on U.S. federal action as the country will potentially "place the US between 2 of only 3 countries in the world to have legalized cannabis for recreational use." 9% of Mexico's population of 131M is estimated to have consumed cannabis in 2018 and the legal market could be worth $1B by 2024, according to BDS Analytics, noted Carey. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY) and Trulieve Cannabis (TCNNF).
NXTC NextCure
$37.41

-1.45 (-3.73%)

07/09/19
BOFA
07/09/19
INITIATION
Target $25
BOFA
Buy
NextCure initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Alec Stranahan started NextCure with a Buy rating and $25 price target. The company has developed a unique drug target discovery platform to identify the next generation of immunotherapies, Stranahan tells investors in a research note. Further, the analyst believes NextCure's cash position will likely be sufficient to advance therapies to late stage clinical trials.
07/10/19
PIPR
07/10/19
NO CHANGE
Target $26
PIPR
Overweight
NextCure should be owned ahead of NC318 data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff recommends owning shares of NextCure ahead of the full Phase I data for NC318 and Phase II expansion cohorts in Q4. NC318 targets Siglec-15 and is differentially expressed from PD-L1 on tumor cells, Tenthoff tells investors in a research note. NC318 achieved one partial response and six patients with stable disease for an "impressive" early disease control rate of 54%, adds the analyst. He reiterates an Overweight rating on NextCure with a $26 price target.
09/04/19
PIPR
09/04/19
NO CHANGE
Target $54
PIPR
Overweight
NextCure price target raised to $54 from $26 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff more than doubled his price target for NextCure to $54 from $26 and reiterates an Overweight rating on the shares. The stock closed Wednesday up 7% to $39.43. Enrollment remains ongoing in the Phase I dose escalation study of NC318 targeting Siglec-15 in advanced solid tumors, Tenthoff tells investors in a research note. While early, NC318 has shown initial signs of activity including, adds the analyst. Tenthoff increased his value for NC318 ahead of Phase I data readout in Q4.
11/11/19
PIPR
11/11/19
NO CHANGE
Target $95
PIPR
Overweight
NextCure price target raised to $95 from $54 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for NextCure to $95 from $54 after the company presented Phase I data on NC318 targeting Siglec-15. The "positive" data show NC318 is active, and NextCure has begun Phase II expansion cohorts in non-small-cell lung carcinoma, ovarian, head and neck and triple negative breast cancer with preliminary data by the end of 2020, Tenthoff tells investors in a research note. He reiterates an Overweight rating on the shares.
HALO Halozyme
$16.77

0.18 (1.09%)

07/01/19
CANT
07/01/19
NO CHANGE
Target $27
CANT
Overweight
Halozyme price target raised to $27 from $24 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Halozyme Therapeutics to $27 from $24 after including potential future royalty revenues from Enhanze-enhanced drugs developed by partner companies. The analyst continues to view the approval and launch of the Enhanze-based products as "fueling sustainable revenue growth" through 2027, with the Darzalex program as the near-term driver. He sees "notable potential" share upside "almost irrespective" of the outcome of the HALO-301 Phase trial in pancreatic cancer later in 2019. Duncan reiterates an Overweight rating on Halozyme.
09/11/19
CANT
09/11/19
NO CHANGE
CANT
Overweight
Halozyme offers 'low-risk/high-reward' event in Q4, says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating on shares of Halozyme Therapeutics after a meeting with the company's CEO left him believing that a "clear read" will be seen with the HALO-301 trial in pancreatic cancer later in 2019. However, the analyst continues to see Halozyme share upside "almost irrespective" of the outcome of the Phase 3 trial in Q4. Investors appreciate the high risk in pancreatic cancer, says Duncan, who sees low expectations for Phase 3 success being priced into the current share price. The company's "growing" Enhanze franchise is the major driver of share value going forward post the HALO-301 readout, Duncan contends. He likes the design and rationale of the study, and therefore sees it as a "low-risk/high-reward" binary event.
11/05/19
LEHM
11/05/19
UPGRADE
Target $16
LEHM
Equal Weight
Halozyme upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Gena Wang upgraded Halozyme Therapeutics to Equal Weight from Underweight with a $16 price target.
11/05/19
LEHM
11/05/19
UPGRADE
Target $16
LEHM
Equal Weight
Halozyme upgraded to Equal Weight after HALO-301 failure at Barclays
Barclays analyst Gena Wang upgraded Halozyme Therapeutics to Equal Weight from Underweight with a price target of $16, down from $17. The analyst believes the HALO-301 failure removed a "major overhang." Strategic refocusing on the core business of Enhanze technology "would further unlock long-term value for the stock," Wang tells investors in a research note.
CYBR CyberArk
$115.30

1.45 (1.27%)

08/07/19
DOTC
08/07/19
NO CHANGE
DOTC
Buy
CyberArk selloff on CRO exit 'overreaction' a buying opportunity, says Dougherty
Dougherty analyst Catharine Trebnick said CyberArk is selling off despite a "solid report" and she would be a buyer amid the weakness, which she views as an overreaction to the Chief Revenue Officer departure. The analyst, who said the company has a strong bench, keeps a Buy rating on CyberArk shares.
08/07/19
JPMS
08/07/19
NO CHANGE
Target $160
JPMS
Overweight
CyberArk price target raised to $160 from $125 at JPMorgan
JPMorgan analyst Sterling Auty raised his price target for CyberArk to $160 from $125 after the June results showed another quarter of "good upside" in revenue and earnings on consistent execution. The analyst notes that Chief Revenue Officer, who has been CRO for the last 2 years and with the company for 20 years, is leaving to focus on board seats on emerging companies and adds that he sees that move as a "natural transition." Auty reiterates an Overweight rating on the shares.
08/21/19
COWN
08/21/19
INITIATION
Target $145
COWN
Outperform
CyberArk initiated with an Outperform at Cowen
Cowen analyst Nick Yako initiated CyberArk with an Outperform as he believes it can deliver 19% annual revenue growth through 2024, given its leadership position in Privilege Access Security, a top growth area in security. The analyst also cited its ability to capture spending from existing customers as well as continuing to add new customers. Yako has a $145 price target on CyberArk shares.
11/08/19
PIPR
11/08/19
INITIATION
Target $120
PIPR
Neutral
CyberArk assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Rob Owens assumed coverage of CyberArk with a Neutral rating and $120 price target.
I Intelsat
$20.39

-2.845 (-12.24%)

04/17/19
GSCO
04/17/19
NO CHANGE
GSCO
Sprint, T-Mobile headlines positive for Dish, Intelsat, says Goldman Sachs
Goldman Sachs analyst Brett Feldman, while taking no view on the outcome of the proposed merger between Sprint (S) and T-Mobile (TMUS), laid out his thoughts for other industry participants following the Wall Street Journal's report that the Department of Justice is unlikely to approve the deal as currently structured. The analyst believes investors will initially see the headlines as negative for the other major wireless carriers, namely AT&T (T) and Verizon (VZ), since they "create uncertainty over long-term industry structure." Further, investors will initially see these headlines as a slight positive for tower operators American Tower (AMT), Crown Castle (CCI) and SBA Communications (SBAC) as they "imply less risk of material cell site decommissioning," Feldman told investors earlier in a research note. The analyst also thinks investors will view the Journal's report as positive for owners of excess spectrum such as Dish (DISH) and Intelsat (I) and a slight positive for cable operators like Altice USA (ATUS), Charter (CHTR) and Comcast (CMCSA).
09/19/19
JPMS
09/19/19
NO CHANGE
Target $32
JPMS
Overweight
Intelsat price target raised to $32 from $27 at JPMorgan
JPMorgan analyst Philip Cusick raised his price target for Intelsat to $32 from $27 and reiterates an Overweight rating on the shares. The analyst believes the Federal Communications Commission and C-Band Alliance are working toward an order that would include 300 MHz of cleared C-Band spectrum, targeting a November order. The analyst estimates ~$26B of total proceeds across 280 MHz. He thinks market is now underpricing the likelihood of Intelsat and the CBA's eventually selling spectrum and "reaping substantial proceeds."
11/12/19
JPMS
11/12/19
DOWNGRADE
Target $22
JPMS
Neutral
Intelsat downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Intelsat to Neutral from Overweight with a $22 price target.
11/12/19
JPMS
11/12/19
DOWNGRADE
Target $22
JPMS
Neutral
Intelsat downgraded to Neutral on 'more complicated' C-Band outlook at JPMorgan
JPMorgan analyst Philip Cusick downgraded Intelsat to Neutral from Overweight and lowered his price target for the shares to $22 from $34 as he sees the C-Band process as more complicated than it seemed "only weeks ago" as pushback for a public rather than private auction of the airwaves coming from Senator Kennedy of Louisiana has gained momentum. He now sees the timing of C-Band monetization further out than he had expected, Cusick said. He also lowered his estimate of C-Band spectrum proceeds to Intelsat to $8B from $10B.

TODAY'S FREE FLY STORIES

PNC

PNC Financial

$158.60

-0.3 (-0.19%)

, PYPL

PayPal

$107.68

2.01 (1.90%)

13:57
12/14/19
12/14
13:57
12/14/19
13:57
Periodicals
PNC clients having trouble connecting to PayPal's Venmo, WSJ reports »

Many of PNC…

PNC

PNC Financial

$158.60

-0.3 (-0.19%)

PYPL

PayPal

$107.68

2.01 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 15

    Jan

BRK.A

Berkshire Hathaway

$338,250.51

-992.49 (-0.29%)

, CMCSA

Comcast

$43.59

0.57 (1.33%)

07:44
12/14/19
12/14
07:44
12/14/19
07:44
Periodicals
Berkshire, Anthem among Barron's top 10 stock picks for 2020 »

Barron's has…

BRK.A

Berkshire Hathaway

$338,250.51

-992.49 (-0.29%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

RDS.B

Royal Dutch Shell

$57.41

-0.19 (-0.33%)

RDS.A

Royal Dutch Shell

$57.44

-0.32 (-0.55%)

PFE

Pfizer

$38.31

-0.23 (-0.60%)

VIAC

ViacomCBS

$38.62

0.83 (2.20%)

ANTM

Anthem

$284.14

-0.405 (-0.14%)

DELL

Dell Technologies

$49.39

-0.11 (-0.22%)

GOOG

Alphabet

$1,348.07

-2.09 (-0.15%)

GOOGL

Alphabet Class A

$1,347.11

-1.4 (-0.10%)

UHAL

Amerco

$360.28

7.57 (2.15%)

UTX

United Technologies

$148.99

-0.5 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Feb

PCG

PG&E

$11.26

-0.49 (-4.17%)

07:38
12/14/19
12/14
07:38
12/14/19
07:38
Hot Stocks
California Governor says PG&E restructuring plan 'falls woefully short' »

California Governor Gavin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

MYGN

Myriad Genetics

$25.58

0.58 (2.32%)

07:31
12/14/19
12/14
07:31
12/14/19
07:31
Hot Stocks
Myriad Genetics says study validates polygenic risk score for breast cancer »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPC

Tutor Perini

$15.73

-0.17 (-1.07%)

07:30
12/14/19
12/14
07:30
12/14/19
07:30
Hot Stocks
Tutor Perini 'disappointed,' will appeal jury verdict in SR 99 Alaskan Way case »

Tutor Perini released a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLRX

BioLineRx

$2.38

-0.23 (-8.81%)

, BD

Budget Group

$0.00

(0.00%)

04:55
12/14/19
12/14
04:55
12/14/19
04:55
Conference/Events
European Society for Medical Oncology to hold a conference »

ESMO Immuno-Oncology…

BLRX

BioLineRx

$2.38

-0.23 (-8.81%)

BD

Budget Group

$0.00

(0.00%)

IDRA

Idera Pharmaceuticals

$1.59

-0.05 (-3.05%)

MRK

Merck

$89.18

0.84 (0.95%)

PFE

Pfizer

$38.31

-0.23 (-0.60%)

NKTR

Nektar

$21.28

-0.53 (-2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

ATNX

Athenex

$14.56

-2.38 (-14.05%)

, MRK

Merck

$89.18

0.84 (0.95%)

04:55
12/14/19
12/14
04:55
12/14/19
04:55
Conference/Events
Society of Surgical Oncology to hold a symposium »

San Antonio Breast Cancer…

ATNX

Athenex

$14.56

-2.38 (-14.05%)

MRK

Merck

$89.18

0.84 (0.95%)

ONCS

OncoSec

$2.00

-0.39 (-16.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

ACB

Aurora Cannabis

$2.63

0.02 (0.77%)

, CRON

Cronos Group

$7.28

-0.03 (-0.41%)

04:55
12/14/19
12/14
04:55
12/14/19
04:55
Conference/Events
MJBizDaily to hold a conference »

Marijuana Business…

ACB

Aurora Cannabis

$2.63

0.02 (0.77%)

CRON

Cronos Group

$7.28

-0.03 (-0.41%)

NFX

Newfield Exploration

$0.00

(0.00%)

CGC

Canopy Growth

$20.69

-0.455 (-2.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDSI

BioDelivery Sciences

$6.40

-0.065 (-1.01%)

04:55
12/14/19
12/14
04:55
12/14/19
04:55
Conference/Events
BioDelivery Sciences management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

AOBC

American Outdoor Brands

$9.23

-0.04 (-0.43%)

, AVCO

Avalon GloboCare

$2.27

-0.06 (-2.58%)

04:55
12/14/19
12/14
04:55
12/14/19
04:55
Conference/Events
Roth Capital to hold a conference »

8th Annual ROTH Deer…

AOBC

American Outdoor Brands

$9.23

-0.04 (-0.43%)

AVCO

Avalon GloboCare

$2.27

-0.06 (-2.58%)

BBSI

Barrett Business

$93.18

1.82 (1.99%)

BNGO

Bionano Genomics

$1.02

0.01 (0.99%)

IRMD

iRadimed

$25.25

-0.52 (-2.02%)

FC

Franklin Covey

$35.21

-0.57 (-1.59%)

NBEV

New Age Beverages

$1.91

-0.015 (-0.78%)

WATT

Energous

$1.99

(0.00%)

EAST

Eastside Distilling

$2.79

-0.12 (-4.12%)

DCTH

Delcath Systems

$0.00

(0.00%)

BOOM

DMC Global

$52.89

0.64 (1.22%)

CLAR

Clarus

$13.47

-0.02 (-0.15%)

JRSH

Jerash Holdings

$6.46

(0.00%)

MCHX

Marchex

$3.68

0.03 (0.82%)

JYNT

Joint Corp.

$17.37

0.28 (1.64%)

SOLY

Soliton

$10.35

-0.005 (-0.05%)

SMSI

Smith Micro

$4.66

0.095 (2.08%)

PWFL

PowerFleet

$6.10

0.05 (0.83%)

OSIS

OSI Systems

$100.60

0.63 (0.63%)

LOVE

Lovesac

$10.80

-1.01 (-8.55%)

VERI

Veritone

$2.73

-0.1 (-3.53%)

WTER

Alkaline Water

$1.09

-0.01 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 19

    Dec

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 29

    Jan

WFT

Weatherford

$0.00

(0.00%)

18:49
12/13/19
12/13
18:49
12/13/19
18:49
Hot Stocks
Weatherford completes financial restructuring, emerges from Chapter 11 »

Weatherford announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$57.71

-0.81 (-1.38%)

18:40
12/13/19
12/13
18:40
12/13/19
18:40
Hot Stocks
Centene CEO: Our big markets are growing, we're gaining share »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

LYV

Live Nation

$64.24

-5.205 (-7.50%)

, ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

18:29
12/13/19
12/13
18:29
12/13/19
18:29
Hot Stocks
S&P announces changes to S&P 400, 500, 600 indices »

S&P Dow Jones Indices…

LYV

Live Nation

$64.24

-5.205 (-7.50%)

ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

STE

Steris

$151.93

-1.745 (-1.14%)

AMG

Affiliated Managers

$85.18

-1.77 (-2.04%)

TRIP

TripAdvisor

$29.24

-0.2 (-0.68%)

MAC

Macerich

$26.04

-0.46 (-1.74%)

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

LEA

Lear

$129.43

-0.84 (-0.64%)

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

UNT

Unit Corp.

$0.83

-0.0626 (-6.98%)

FTR

Frontier Communications

$0.68

0.0315 (4.84%)

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

GVA

Granite Construction

$26.21

-1.335 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 23

    Mar

PLAN

Anaplan

$51.80

1.44 (2.86%)

18:23
12/13/19
12/13
18:23
12/13/19
18:23
Hot Stocks
Anaplan CEO: Digitization has really started to accelerate »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPX

WPX Energy

$10.92

-0.24 (-2.15%)

18:08
12/13/19
12/13
18:08
12/13/19
18:08
Periodicals
WPX Energy in talks to acquire Felix Energy assets for $2.5B, Bloomberg says »

WPX Energy is in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

HLIT

Harmonic

$7.94

-0.25 (-3.05%)

17:47
12/13/19
12/13
17:47
12/13/19
17:47
Hot Stocks
Harmonic CFO sells 28K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$32.84

(0.00%)

17:36
12/13/19
12/13
17:36
12/13/19
17:36
Hot Stocks
Breaking Hot Stocks news story on Horizon Pharma »

Horizon Pharma up 9.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 08

    Mar

AMRN

Amarin

$24.12

1.12 (4.87%)

17:33
12/13/19
12/13
17:33
12/13/19
17:33
Hot Stocks
Breaking Hot Stocks news story on Amarin »

Amarin rises 1.4% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

THMO

ThermoGenesis

$2.88

(0.00%)

17:31
12/13/19
12/13
17:31
12/13/19
17:31
Syndicate
Breaking Syndicate news story on ThermoGenesis »

ThermoGenesis files $30M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

17:30
12/13/19
12/13
17:30
12/13/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Amarin 

Amarin trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

QTNT

Quotient

$8.60

-0.165 (-1.88%)

17:28
12/13/19
12/13
17:28
12/13/19
17:28
Syndicate
Breaking Syndicate news story on Quotient »

Quotient files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

, GVA

Granite Construction

$26.21

-1.335 (-4.85%)

17:27
12/13/19
12/13
17:27
12/13/19
17:27
Hot Stocks
Breaking Hot Stocks news story on Arrowhead, Granite Construction »

Arrowhead to replace…

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

GVA

Granite Construction

$26.21

-1.335 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

, SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

17:25
12/13/19
12/13
17:25
12/13/19
17:25
Hot Stocks
Oasis, Southwestern to replace Unit Corp., Frontier in S&P 600 at open on 12/23 »

Oasis Petroleum (OAS) and…

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

UNT

Unit Corp.

$0.83

-0.0626 (-6.98%)

FTR

Frontier Communications

$0.68

0.0315 (4.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

AMRN

Amarin

$24.12

1.12 (4.87%)

17:24
12/13/19
12/13
17:24
12/13/19
17:24
Hot Stocks
Amarin raises guidance after FDA approves Vascepa »

Amarin (AMRN) shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

, LEA

Lear

$129.43

-0.84 (-0.64%)

17:22
12/13/19
12/13
17:22
12/13/19
17:22
Hot Stocks
Grand Canyon, Lear to replace Oasis, Southwestern in S&P 400 at open on 12/23 »

Grand Canyon Education…

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

LEA

Lear

$129.43

-0.84 (-0.64%)

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.